Current rates of sodium-glucose link transporter 2 inhibitors (SGLT2i) prescribing in type 2 diabetes show no evidence of prioritisation in those with cardiovascular disease and heart failure
DIABETIC MEDICINE（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要